Donna Gutterman
12Patents
6h-index
6Co-inventors
59Inventor score
Filing activity: May 22, 2000 → Aug 30, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10758497B2 | Treatment of fragile x syndrome with cannabidiol | Human Necessities | 12 | Active |
| US10568848B2 | Treatment of autism with cannabidiol | Human Necessities | 12 | Active |
| US10213390B1 | Treatment of fragile X syndrome with cannabidiol | Human Necessities | 12 | Active |
| US10314792B2 | Treatment of autism with cannabidiol | Human Necessities | 12 | Active |
| US10471022B2 | Treatment of fragile X syndrome with cannabidiol | Human Necessities | 12 | Active |
| US7189753B1 | Preemptive prophylaxis of migraine | Human Necessities | 9 | Expired |
| US11458109B2 | Treatment of 22Q11.2 deletion syndrome with cannabidiol | Human Necessities | 3 | Active |
| US11458110B2 | Treatment of Fragile X Syndrome with cannabidiol | Human Necessities | 2 | Active |
| US11779549B2 | Treatment of Fragile X Syndrome with cannabidiol | Human Necessities | 1 | Active |
| US12213951B2 | Treatment of autism with cannabidiol | Human Necessities | 0 | Active |
| US12226373B2 | Treatment of fragile X syndrome with cannabidiol | Human Necessities | 0 | Active |
| US12186282B2 | Treatment of 22Q11.2 deletion syndrome with cannabidiol | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.